Mirum Pharmaceuticals, Inc. (NasdaqGM: MIRM)
Health Care · Biotechnology · US
$86.83
+0.95% today · +19.2% 1Y
Mirum Pharmaceuticals, Inc. (NasdaqGM: MIRM) operates in the Biotechnology industry within the Health Care sector. The company is valued at $5.58B and employs 433 people.
Over the last twelve months the share price has gained 19.2%, trading between 63.23 and 130.00.
Tweenvest scores Mirum Pharmaceuticals, Inc. across four factors: quality 43/100, value 46/100. Its strongest factor is value.
MIRM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $5.58B
- Revenue (TTM)
- $618.07M
- P/E
- —
- EPS
- -15.34
- Dividend yield
- —
- Beta (5Y)
- 0.61
- 52-week high
- $130.00
- 52-week low
- $63.23
- Avg volume (3M)
- —
- Shares outstanding
- 64.93M
- Employees
- 433
- Next earnings
- —
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
- ISIN
- US6047491013
- Founded
- 2018
- Listed since
- Jul 18, 2019
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plcNasdaqGS: KNSA | $6.22B | $80.31 | +0.66% |
| Biocon LimitedNSEI: BIOCON | $5.88B | Rs349.40 | -5.75% |
| CG Oncology, Inc.NasdaqGS: CGON | $5.66B | $63.58 | -0.38% |
| Erasca, Inc.NasdaqGS: ERAS | $5.61B | $15.63 | -2.53% |
| Oruka Therapeutics, Inc.NasdaqCM: ABIO | $5.44B | $— | — |
| Oruka Therapeutics, Inc.NasdaqGM: ORKA | $5.44B | $80.29 | -2.22% |
| PTC Therapeutics, Inc.NasdaqGS: PTCT | $5.40B | $63.65 | -1.62% |
| Cogent Biosciences, Inc.NasdaqGS: COGT | $5.38B | $30.38 | -2.00% |
Figures last refreshed Oct 11, 2026.